Skip to content

Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease

Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002593
Enrollment
Unknown
Registered
2019-09-12
Start date
2019-09-11
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

parkinson disease

Interventions

Sponsors

Kaida Wang
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria of PD Chinese and Western medicine; (2) TCM syndrome differentiation belongs to spleen and lung deficiency; (3) Those aged 55-80 years; (4) Modified HY stage <= 2.5; (5) Conscious, vital signs are stable; (6) Those who voluntarily accept this experimental study and informed consent.

Exclusion criteria

Exclusion criteria: (1) Parkinson's syndrome and Parkinson's superposition syndrome caused by various causes such as cerebrovascular disease and poisoning; (2) Those with major diseases such as severe liver and kidney, blood, tumor, endocrine disease or pain (3) Those who are involved in other drug clinical trials; (4) Psychiatric patients; (5) Those who have a history of ugly drinking or a history of drug abuse.

Design outcomes

Primary

MeasureTime frame
Parkinson's Non-motor syndrome Scale (NMSS);Unified Parkinson's Disease Rating Scale (UPDRSI II III);

Countries

China

Contacts

Public ContactKaida Wang

The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine

baoyushou3@163.com+86 13854115876

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026